This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 42.3 kDa. The protein migrates as 53-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Loaded Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) on Protein A Biosensor, can bind Human OX40, His Tag (Cat. No. OX0-H5224) with an affinity constant of 2 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
FACS assay shows that recombinant Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) can bind to 293T cell overexpressing human OX40. The concentration of OX40 Ligand is 0.003 μg/ml (Routinely tested).
FACS analysis shows that the binding of Human OX40 Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OXL-H5250) to 293T overexpressing OX40 was inhibited by increasing concentration of neutralizing anti-OX40 antibody. The concentration of OX40 Ligand used is 0.002 μg/ml. IC50=3.021 μg/ml (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $350.00
Price(USD) : $2310.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.